![[ICO]](/icons/blank.gif){kind=icon}
![[PARENTDIR]](/icons/back.gif){kind=icon}
![[ ]](/icons/layout.gif){kind=icon}
| Name | Last modified | Size | Description |
|---|---|---|---|---|
| Parent Directory | - | ||
| Fernandez_Ruiz ESGICH_Biologicals_Introduction.pdf | 2022-02-19 16:27 | 386K | |
| Baddley.anti_TNF.ESGICH.pdf | 2022-02-19 16:27 | 587K | |
| Mikulska(1).CMI.pdf | 2022-02-19 16:27 | 593K | |
| Gil-Redelman.ESGICH_Immune checkpoint inhibitors cell adhesion inhibitors sphingosine-1-phosphate.pdf | 2022-02-19 16:27 | 632K | |
| Aguilar.Onco.ESGICH Consensus in targeted therapies- cell surface receptors.pdf | 2022-02-19 16:27 | 722K | |
| Reinwald. tyrosine kinase and mTOR.ESGICH.pdf | 2022-02-19 16:27 | 845K | |
| Whintrop.Agents targeting interleukins immunoglobulins complement.pdf | 2022-02-19 16:27 | 1.0M | |
| Drgona_etal. ESGICH Consensus Document on the safety of targeted and biological the.pdf | 2022-02-19 16:27 | 8.5M | |